# A Two-armed Real-world Study of Ozempic (OW Semaglutide) to Evaluate Its Adherence and Persistence Compared With Other Anti-diabetic Drugs Among Adult T2DM Patients in China

> **NCT07456774** · — · NOT_YET_RECRUITING · sponsor: **Novo Nordisk A/S** · enrollment: 100000 (estimated)

## Conditions studied

- Type 2 Diabetes

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT07456774
- **Lead sponsor:** Novo Nordisk A/S
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-02-13
- **Primary completion:** 2026-08-31
- **Final completion:** 2026-08-31
- **Target enrollment:** 100000 (ESTIMATED)
- **Last updated:** 2026-03-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07456774

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07456774, "A Two-armed Real-world Study of Ozempic (OW Semaglutide) to Evaluate Its Adherence and Persistence Compared With Other Anti-diabetic Drugs Among Adult T2DM Patients in China". Retrieved via AI Analytics 2026-08-12 from https://api.ai-analytics.org/clinical/NCT07456774. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*